Abstracts tagged "patient outcomes and systemic sclerosis"

Abstract Number: 790 • 2018 ACR/ARHP Annual Meeting
Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet
Kelly Jensen¹, Linda Wang², Rosemary Kovacic², Veronika K. Jaeger³, Monika Lammi⁴ and Lesley Ann Saketkoo⁵, ¹Tulane University School of Medicine, New Orleans, LA, ²Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, ³Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁴GI Motility Program at Ochsner Medical Center, New Orleans, LA, ⁵Tulane, New Orleans, LA
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease affecting multiple organ systems including vascular, musculoskeletal, cardiac, renal, pulmonary, and gastrointestinal (GI). 90% of SSc…
Abstract Number: 1739 • 2018 ACR/ARHP Annual Meeting
What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?
Jessica Zhu¹, Craig Gale², Joshua Biber³, Mandana Nikpour⁴, Murray Baron⁵ and Tracy M. Frech⁶, ¹School of Medicine, University of Utah, Salt Lake City, UT, ²Bioinformatics, University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴The University of Melbourne, Melbourne, Australia, Melbourne, Australia, ⁵Department of Medicine, McGill University, Montreal, QC, Canada, ⁶Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: The implementation of patient reported outcome measures (PROMs) is increasingly recognized as a critical aspect of clinical practice. The use of gastrointestinal (GI) PROMs…
Abstract Number: 2687 • 2018 ACR/ARHP Annual Meeting
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
Vivek Nagaraja¹, John Powers², Celia J. F. Lin³, Benjamin Brennan⁴, Veronica J. Berrocal⁵ and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Maryland School of Medicine, Rockville, MD, ³Genentech, Inc., South San Francisco, CA, ⁴School of Public Health, University of Michigan, Ann Arbor, MI, ⁵Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment benefit is demonstrated by evidence that interventions have positive impacts on how patients feel, function, and/or survive (FDA Guidance, 21CFR314.510). The ACR CRISS,…
Abstract Number: 2668 • 2017 ACR/ARHP Annual Meeting
Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients
Yossra A Suliman¹, Suzanne Kafaja², Mohamed Alemam³, yasser Shaweesh⁴, Kasra Tavakoli⁵ and Daniel E. Furst⁶, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁴John H. Stroger Jr. Hospital of cook county, chicago, IL, ⁵Department of medicine, university of California Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Gastrointestinal tract (GIT) involvement in systemic sclerosis (SSc) is the most common internal organ involvement. Among the few validated patient-reported outcome measures for GI…
Abstract Number: 2694 • 2017 ACR/ARHP Annual Meeting
Performance of Patient-Reported Outcomes Measurement Information Systems (PROMIS) Promis-29 and Promis Self-Efficacy in Systemic Sclerosis (SSc)
Janet L. Poole¹, Veronica J. Berrocal², Jennifer Serrano³, Erica Bush³ and Dinesh Khanna³, ¹Health Sciences Ctr OT Program, 1 University of New Mexico, Albuquerque, NM, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Patient reported outcomes are important to measure the effectiveness of non-pharmacological and pharmacological interventions. The goal of PROMIS is to develop standardized items banks…
Abstract Number: 2718 • 2014 ACR/ARHP Annual Meeting
The UCLA Gastrointestinal Tract Questionnaire (GIT)2.0 and GI Visual Analogue Scale(GI-VAS) Reflect Different Aspects of GI Involvement in Systemic Sclerosis
Yossra Suliman^1,2, Yasser Shaweesh³, Suzanne Kafaja^4,5,6, Lewei Duan⁷ and Daniel E. Furst⁸, ¹Division of Rheumatology, Department of Medicine., David Geffen School of Medicine, University of California Los Angeles,, Los Angeles, CA, ²Rheumatology and Rehabilitation department, Faculty of Medicine, Assiut university, Assiut, Egypt, ³Division of Rheumatology, Department of Medicine., David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ⁴Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁵Medicine, University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁶David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁷David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁸University of California at Los Angeles, Los Angeles, CA
Background/Purpose UCLA GIT2.0 is a validated measure for assessing the severity of gastrointestinal involvement in systemic sclerosis patients (SSc) patients; GI VAS is also a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].